Cost-Effectiveness of Tafamidis Therapy for Transthyretin Amyloid Cardiomyopathy.

ABSTRACT:

Background

In patients with transthyretin amyloid cardiomyopathy, tafamidis reduces all-cause mortality and cardiovascular hospitalizations and slows decline in quality of life compared with placebo. In May 2019, tafamidis received expedited approval from the US Food and Drug Administration as a breakthrough drug for a rare disease. However, at $225 000 per year, it is the most expensive cardiovascular drug ever launched in the United States, and its long-term cost-effectiveness and budget impact are uncertain. We therefore aimed to estimate the cost-effectiveness of tafamidis and its potential effect on US health care spending.

Methods

We developed a Markov model of patients with wild-type or variant transthyretin amyloid cardiomyopathy and heart failure (mean age, 74.5 yea

SUBMITTER: Kazi DS 

PROVIDER: S-EPMC7156331 | biostudies-literature | 2020 Apr

REPOSITORIES: biostudies-literature